-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
-
Summary
-
Estrella Immunopharma, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q3 2021 to Q2 2024.
- Estrella Immunopharma, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending June 30, 2024 was $4.48M, a 75% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)